Khaitan & Co advised Reliance Industries Ltd ("RIL") in connection with its strategic partnership with Meta Platforms, Inc. (“Meta”) for the development of Meta’s first AI-enabled data centre in India. Pursuant to the partnership, RIL will develop a built-to-suit 168 MW hyperscale data centre in Jamnagar, Gujarat, which Meta will lease to support its artificial intelligence and computing requirements.
Khaitan & Co advised Embio Ltd (“Embio”) in relation investment by True North, a leading private equity fund, in Embio.
The firm advised Embio Limited on all legal aspects of the transaction.
Khaitan & Co advised Bain Capital in relation to the formation of a 50:50 joint venture between GSS India Opportunities AIF Scheme I (represented by its fund manager, Bain Capital Advisors (India) Pvt Ltd) and Brigade Enterprises Ltd, to develop and manage a 2 million square feet mixed-use project, comprising of a Grade A office space and a 5-star hotel in Bengaluru.
Khaitan & Co advised Chalet Hotels Ltd (formerly Chalet Hotels Pvt Ltd) with the acquisition of 100% stake of Seasons Hotels Pvt Ltd owning a 144-room hotel ‘Inder Residency Resort & Spa, Udaipur’ in the state of Rajasthan from its shareholders for a total consideration of approximately INR 171 crores.
Khaitan & Co advised FMC Corporation on its divestment of India crop protection commercial business to Crystal Crop Protection Limited for a total consideration of USD 252 million.
Khaitan & Co advised the consortium of Oberoi Realty Ltd, Shree Naman Developers Pvt Ltd and JM Financial Properties and Holdings Ltd on the implementation of the NCLT-approved resolution plan and acquisition of Hotel Horizon Pvt Ltd for a total consideration of INR 920 crores.
Pirabu is a Partner in the Real Estate practice group. Prior to joining the Firm, Pirabu was a counsel at Shardul Amarchand Mangaldas, Chennai.
Khaitan & Co is representing Amneal Pharmaceuticals, LLC (Amneal) as India counsels, alongside Simpson Thacher & Bartlett LLP in relation to its announced agreement to acquire 100% of Kashiv Biosciences LLC ("Kashiv"), a vertically integrated biopharmaceutical company incorporated in the United States of America, with 2 (two) subsidiaries in India (namely, Kashiv Biosciences Pvt Ltd and Kashiv Research Pvt Ltd), in a transaction with consideration that includes USD 375 million of cash and USD 375 mill
'Principal Act: Karnataka Rent Act, 1999 (Karnataka Act 34 of 2001). Amendment Act: Karnataka Rent (Amendment) Act, 2025 (Karnataka Act No 07 of 2026)'
Khaitan & Co advised Everstone Capital on its partnership with the founding promoters of Apothecon Pharmaceuticals Pvt Ltd (India) and Navinta III Inc.
